You are here

Asciminib - Phase 3 Asemble Trial

Recruitment period: 
27 July 2021
Trial period: 
27 July 2021
For newly diagnosed patients: 

Asciminib, a first-in-class STAMP inhibitor, may be a new treatment option for patients with chronic myeloid leukaemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine kinase inhibitors.

ASCEMBL Phase 3 trial